Patients with active psoriatic arthritis who have an inadequate response to TNF inhibitors, mainly those with elevated C-reactive protein levels, may benefit from guselkumab plus golimumab therapy.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/tnf-plus-il-23-inhibition-psoriatic-arthritis-better-than-il-2026a1000fgj?src=rss
Author :
Publish date : 2026-05-13 12:43:00
Copyright for syndicated content belongs to the linked Source.